Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

NCT02118987 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Drug Allergy

Interventions

DRUG: Omalizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]